Head to Head Comparison: AzurRx BioPharma (NASDAQ:AZRX) vs. Its Rivals

AzurRx BioPharma (NASDAQ: AZRX) is one of 106 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare AzurRx BioPharma to similar companies based on the strength of its valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Risk and Volatility

AzurRx BioPharma has a beta of -0.98, suggesting that its share price is 198% less volatile than the S&P 500. Comparatively, AzurRx BioPharma’s competitors have a beta of 0.87, suggesting that their average share price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares AzurRx BioPharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AzurRx BioPharma N/A -$14.59 million N/A
AzurRx BioPharma Competitors $8.58 billion $861.67 million 156.46

AzurRx BioPharma’s competitors have higher revenue and earnings than AzurRx BioPharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for AzurRx BioPharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AzurRx BioPharma 0 0 1 0 3.00
AzurRx BioPharma Competitors 1005 4004 6993 191 2.52

AzurRx BioPharma currently has a consensus target price of $8.00, indicating a potential upside of 159.74%. As a group, “Pharmaceuticals” companies have a potential upside of 24.89%. Given AzurRx BioPharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe AzurRx BioPharma is more favorable than its competitors.

Institutional and Insider Ownership

8.1% of AzurRx BioPharma shares are owned by institutional investors. Comparatively, 43.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.1% of AzurRx BioPharma shares are owned by insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares AzurRx BioPharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AzurRx BioPharma N/A -470.85% -205.40%
AzurRx BioPharma Competitors -2,433.46% -67.10% -7.87%


AzurRx BioPharma competitors beat AzurRx BioPharma on 8 of the 12 factors compared.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply